肿瘤坏死因子抑制剂治疗后发生的播散性分枝杆菌感染，揭示了先天性免疫缺陷。
Disseminated mycobacterial infections after tumor necrosis factor inhibitor use, revealing inborn errors of immunity.
机构信息
Division of Pulmonary, Allergy, and Sleep Medicine, Mayo Clinic, Jacksonville, USA.
Division of Infectious Diseases, Mayo Clinic, Jacksonville, USA.
出版信息
Int J Infect Dis. 2023 Jun;131:162-165. doi: 10.1016/j.ijid.2023.04.007. Epub 2023 Apr 8.
Abstract
Tumor necrosis factor-a inhibitors can be associated with increased risk of infections, particularly reactivation of latent tuberculosis or nontuberculous mycobacterium (NTM). However, because disseminated NTM is rare, inborn errors of immunity should be considered. We present three patients with disseminated NTM after tumor necrosis factor-a inhibitor use who were found to have inborn errors of immunity.
摘要
肿瘤坏死因子-α抑制剂可增加感染风险，特别是潜伏性结核分枝杆菌或非结核分枝杆菌（NTM）的再激活。然而，由于播散性 NTM 较为罕见，因此应考虑固有免疫缺陷。我们报告了 3 例使用肿瘤坏死因子-α抑制剂后发生播散性 NTM 的患者，这些患者被发现存在固有免疫缺陷。
相似文献
1
Disseminated mycobacterial infections after tumor necrosis factor inhibitor use, revealing inborn errors of immunity.肿瘤坏死因子抑制剂治疗后发生的播散性分枝杆菌感染，揭示了先天性免疫缺陷。
Int J Infect Dis. 2023 Jun;131:162-165. doi: 10.1016/j.ijid.2023.04.007. Epub 2023 Apr 8.
2
TNF inhibitors increase the risk of nontuberculous mycobacteria in patients with seropositive rheumatoid arthritis in a mycobacterium tuberculosis endemic area.TNF 抑制剂会增加分枝杆菌结核流行地区血清阳性类风湿关节炎患者发生非结核分枝杆菌的风险。
Sci Rep. 2022 Mar 7;12(1):4003. doi: 10.1038/s41598-022-07968-w.
3
Disseminated nontuberculous mycobacterial infection with cryptic immunodeficiency mimicking malignancy: a case report.播散性非结核分枝杆菌感染伴隐匿性免疫缺陷，酷似恶性肿瘤：病例报告。
BMC Pulm Med. 2022 Nov 29;22(1):452. doi: 10.1186/s12890-022-02227-0.
4
Disseminated nontuberculous mycobacteria infection in an immunocompetent host: A case report.免疫功能正常宿主播散性非结核分枝杆菌感染：病例报告。
Medicine (Baltimore). 2023 Jan 6;102(1):e32416. doi: 10.1097/MD.0000000000032416.
5
Nontuberculous mycobacterial infections in cystic fibrosis.囊性纤维化中的非结核分枝杆菌感染。
Clin Chest Med. 2015 Mar;36(1):101-15. doi: 10.1016/j.ccm.2014.11.003.
6
Non-tuberculous mycobacteria in children: muddying the waters of tuberculosis diagnosis.儿童中的非结核分枝杆菌：结核诊断的“浑水”。
Lancet Respir Med. 2015 Mar;3(3):244-56. doi: 10.1016/S2213-2600(15)00062-4. Epub 2015 Mar 9.
7
Nontuberculous mycobacterial (NTM) lung disease: the top ten essentials.非结核分枝杆菌（NTM）肺病：十大要点
Respir Med. 2014 Mar;108(3):417-25. doi: 10.1016/j.rmed.2013.09.014. Epub 2013 Sep 25.
8
Overview of nontuberculous mycobacterial disease in children.儿童非结核分枝杆菌病概述
J Paediatr Child Health. 2021 Jan;57(1):15-18. doi: 10.1111/jpc.15257. Epub 2021 Jan 6.
9
Medical Management of Pulmonary Nontuberculous Mycobacterial Disease.非结核分枝杆菌肺病的医学管理
Thorac Surg Clin. 2019 Feb;29(1):65-76. doi: 10.1016/j.thorsurg.2018.09.001.
10
Management of nontuberculous mycobacterial infection in the elderly.老年人非结核分枝杆菌感染的管理。
Eur J Intern Med. 2014 Apr;25(4):356-63. doi: 10.1016/j.ejim.2014.03.008. Epub 2014 Mar 29.
引用本文的文献
1
Management of tuberculosis risk, screening and preventive therapy in patients with chronic autoimmune arthritis undergoing biotechnological and targeted immunosuppressive agents.接受生物技术和靶向免疫抑制剂治疗的慢性自身免疫性关节炎患者的结核病风险管理、筛查及预防性治疗
Front Immunol. 2025 Feb 3;16:1494283. doi: 10.3389/fimmu.2025.1494283. eCollection 2025.
2
Clinical analysis and risk factors associated with poor prognosis in nontuberculous mycobacterial infection.非结核分枝杆菌感染预后不良的临床分析及相关危险因素
Virulence. 2025 Dec;16(1):2459313. doi: 10.1080/21505594.2025.2459313. Epub 2025 Feb 3.
3
Evaluation of Inborn Errors of Immunity Among Patients with Opportunistic Pulmonary Infection.机会性肺部感染患者免疫缺陷病的评估
Clin Chest Med. 2025 Mar;46(1):61-75. doi: 10.1016/j.ccm.2024.10.005. Epub 2024 Nov 29.
4
Association of Tumor Necrosis Factor Inhibitors with the Risk of Nontuberculous Mycobacterial Infection in Patients with Rheumatoid Arthritis: A Nationwide Cohort Study.肿瘤坏死因子抑制剂与类风湿关节炎患者非结核分枝杆菌感染风险的关联：一项全国性队列研究
J Clin Med. 2023 Nov 9;12(22):6998. doi: 10.3390/jcm12226998.
本文引用的文献
1
Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee.人类先天性免疫缺陷：国际免疫学联盟专家委员会 2022 年更新的分类。
J Clin Immunol. 2022 Oct;42(7):1473-1507. doi: 10.1007/s10875-022-01289-3. Epub 2022 Jun 24.
2
Infections in Patients with Chronic Granulomatous Disease Treated with Tumor Necrosis Factor Alpha Blockers for Inflammatory Complications.使用肿瘤坏死因子α阻滞剂治疗慢性肉芽肿病患者炎症并发症时的感染情况。
J Clin Immunol. 2021 Jan;41(1):185-193. doi: 10.1007/s10875-020-00901-8. Epub 2020 Nov 4.
3
Mendelian susceptibility to mycobacterial disease: 2014-2018 update.孟德尔遗传易感性对分枝杆菌病的影响：2014-2018 年更新。
Immunol Cell Biol. 2019 Apr;97(4):360-367. doi: 10.1111/imcb.12210. Epub 2018 Oct 25.
4
Human IκBα Gain of Function: a Severe and Syndromic Immunodeficiency.人类IκBα功能获得：一种严重的综合征性免疫缺陷。
J Clin Immunol. 2017 Jul;37(5):397-412. doi: 10.1007/s10875-017-0400-z. Epub 2017 Jun 9.
5
Host susceptibility to non-tuberculous mycobacterial infections.宿主对非结核分枝杆菌感染的易感性。
Lancet Infect Dis. 2015 Aug;15(8):968-80. doi: 10.1016/S1473-3099(15)00089-4. Epub 2015 Jun 3.
6
GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity.GATA2 缺陷：一种造血、淋巴和免疫功能多样的疾病。
Blood. 2014 Feb 6;123(6):809-21. doi: 10.1182/blood-2013-07-515528. Epub 2013 Nov 13.
7
Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome.GATA2 基因突变与常染色体显性遗传和散发性单核细胞减少症和分枝杆菌感染（MonoMAC）综合征有关。
Blood. 2011 Sep 8;118(10):2653-5. doi: 10.1182/blood-2011-05-356352. Epub 2011 Jun 13.
8
Complications of tumor necrosis factor-α blockade in chronic granulomatous disease-related colitis.肿瘤坏死因子-α 阻断在慢性肉芽肿病相关性结肠炎中的并发症。
Clin Infect Dis. 2010 Dec 15;51(12):1429-34. doi: 10.1086/657308. Epub 2010 Nov 8.
9
Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy.非结核分枝杆菌感染与抗肿瘤坏死因子-α治疗。
Emerg Infect Dis. 2009 Oct;15(10):1556-61. doi: 10.3201/eid1510.090310.
10
Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies.显性和隐性干扰素γ受体1缺陷的临床特征
Lancet. 2004;364(9451):2113-21. doi: 10.1016/S0140-6736(04)17552-1.
Zotero 插件